News

In the media
Press releases

Press Releases

11/04/2024
BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT

10/21/2024

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

10/18/2024

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

10/16/2024

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
10/03/2024
Bright Minds Biosciences announces participation in the upcoming scientific conferences and partnering events

09/19/2024

Bright Minds Biosciences to Host Investor & Analyst KOL Eventon September 25th

09/12/2024

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

02/14/2024

Bright Minds – 2024 AGM Notice and Information Circular

02/14/2024

Bright Minds – Proxy – 2024 AGM

02/14/2024

Bright Minds – Financial Statements Request Form

12/06/2023

Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management

08/08/2023

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data fromits First-in-Human Phase 1 Study of Lead Compound, BMB-101

07/20/2023

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

07/11/2023

Bright Minds Announces Effective Date of Share Consolidation

06/22/2023

Bright Minds Announces Proposed Share Consolidation

04/19/2023

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

04/10/2023

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

02/27/2023

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

02/17/2023

Bright Minds Biosciences Announces Non-Executive Director Appointment

02/08/2023

Bright Minds Bioscienes Announces Receipt of NASDAQ Deficiency Letter Regarding Independent Director and Audit Committee Requirements

01/27/2023

Bright Minds Biosciences announces receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

12/2/2022

Bright Minds Biosciences announces Closing of Non-Brokered Private Placement

11/28/2022


Bright Minds Biosciences announces Non-Brokered Private Placement

11/22/2022

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer

09/13/2022

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

08/31/2022

Bright Minds Biosciences Initiates Dosing in Phase IClinical Trial of BMB-101 for Dravet Syndrome

08/30/2022

Bright Minds Biosciences Announces Closing of $4 Million Unit offering  

08/23/2022

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

08/22/2022

Bright Minds Announces Overnight Marketed offering of Units

08/18/2022

Bright Minds Biosciences Comments on Recent Trading Activity

06/27/2022

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

05/12/2022

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

05/02/2022

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

04/19/2022

Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

03/14/2022

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

03/09/2022

Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference  

01/04/2022

Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

12/06/2021

Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference

11/30/2021

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

11/03/2021

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

10/07/2021

Bright Minds Biosciencesto Present at the LD Micro Main Event Small Cap Investment Conference

09/22/2021

Bright Minds Biosciences Provides Scientific Update

08/09/2021

Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance

08/18/2021

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

06/16/2021

Bright Minds Biosciences Announces Application to List on Nasdaq

06/14/2021

Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team

06/11/2021

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

06/09/2021

Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

05/17/2021

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

05/11/2021

Bright Minds Biosciences to Present at the Benzinga Global Small Cap Conference

05/04/2021

Bright Minds Biosciences Announces Stock Option Grants

04/27/2021

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team

04/23/2021

Bright Minds Enters Exclusive License Agreement with the University of Illinois

03/17/2021

Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

03/15/2021

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows an Over 50% Decrease in Opioid Self-Administration in a Predictive Rodent Model

03/10/2021

Bright Minds Biosciences to Present at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing the Global Mental Health Crisis

03/03/2021

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating

02/23/2021

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of Units

02/22/2021

Bright Minds Biosciences Inc. Announces Marketed Public Offering

02/10/2021

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth

02/05/2021

Bright Minds Biosciences Announces Listing on Canadian Stock Exchange

In the Media

11/24/2021

A vision for “next generation” psychedelic medicines to treat neurological conditions  

11/09/2021

Psychedelic Company Lists on NASDAQ as ‘DRUG’

08/26/2021

Modulating Serotonin with Psychedelics to Treat Neuropsychiatric Conditions

07/12/2021

Investment in Science has Been Rising for Years, but the Biotech and Health Sectors are Currently Getting all the Attention

07/07/2021

Mental Health is Attracting Investors, and it’s Just Getting Started

07/04/2021

Psychedelic medicine companies to watch

06/30/2021

3 Trends Driving the Next Wave of Business Investments

06/24/2021

Pharmaceuticals And Brain Health: What’s The Next Step For The Biotech Industry?

02/02/2021

Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more

12/17/2020

Neo Kuma psychedelics VC fund interview: The lawyer who started the UK’s first dedicated psychedelics venture fund lays out how she placed her initial bets

12/16/2020

New Magic Mushrooms Could Fix Depression, Addiction, Epilepsy, and More

11/25/2020

Mental illness is on the rise due to COVID-19. Could psychedelic drugs be the ‘game changer’?

08/17/2020

After Legal Win, What’s Next for Magic Mushrooms?

05/15/2020

This Drug Designer Is Creating a New Psychedelic to Treat Anxiety and Depression

08/12/2020

From Troubled to Bright Minds: One Company’s Search for More Effective Psychedelics

06/15/2020

2nd Gen Psychedelic Drugs For Depression Can Be Safer For Older Adults